POM

6-K - POMDOCTOR Ltd (0001877971) (Filer)

3 - POMDOCTOR Ltd (0001877971) (Issuer)

6-K - POMDOCTOR Ltd (0001877971) (Filer)

3 - POMDOCTOR Ltd (0001877971) (Issuer)

3 - POMDOCTOR Ltd (0001877971) (Issuer)

3 - POMDOCTOR Ltd (0001877971) (Issuer)

3 - POMDOCTOR Ltd (0001877971) (Issuer)

3 - POMDOCTOR Ltd (0001877971) (Issuer)

GUANGZHOU, China, March 13, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade centered on the core track of "artificial intelligence ("AI") + medical-grade smart wearables + full-cycle chronic disease management". The Company plans to accelerate related technology research and development ("R&D") and scenario-based implementation by leveraging its extensive medical resources and strong compliance capabilities. Over the long run, Pomdoctor aims to build a closed-loop chronic disease management ecosystem integrating hardware, data, algorithms and servi

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Feb. 4, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced a strategic initiative to deepen the integration of its platform with China's national and local coordinated medical insurance systems across major cities nationwide. This initiative is expected to significantly expand the Company's market reach and enhance its service offerings, delivering greater convenience and richer functionality for partner internet hospitals, pharmacies, and patients. Since 2018, China has actively promoted internet-based medical services through a series of policy guide

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Feb. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced that it has received a written notification (the "Deficiency Letter") from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated January 29, 2026, indicating that for the last 33 consecutive business days, the closing bid price of the Company's American depositary shares (the "ADSs") was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Deficiency Letter has no current effect on the listing o

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Jan. 16, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced significant progress in its strategic collaboration with leading domestic pharmaceutical companies to accelerate the growth of its internet hospital business. The Company expects these partnerships to become a core component of its long-term strategy to expand online hospital operations and enhance overall profitability. Against the backdrop of China's accelerating population aging and evolving demographic structure, the domestic internet hospital and online pharmaceutical sales market has exp

6-K - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced its unaudited financial results for the six months ended June 30, 2025. Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor. Despite a challenging macroeconomic environment and intensified market competition, we strived to strengthen our market coverage and penetration, while optimizing and diversifying our revenue streams through

S-8 - POMDOCTOR Ltd (0001877971) (Filer)

GUANGZHOU, China, Oct. 10, 2025 /PRNewswire/ -- POMDOCTOR LIMITED (NASDAQ:POM) (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the underwriter of its initial public offering (the "Offering") has exercised in full its option to purchase an additional 750,000 American Depositary Shares ("ADSs") at a public offering price of $4.00 per ADS to cover over-allotments. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. Gross proceeds to the Company from the offering, including funds received from the prior closing and exercise of this over-allotment option, totaled $23,000,016, before